European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 134, Issue 1 , Pages 3-8, September 2007

Prevention and treatment of uterine bleeding in hematologic malignancy

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Brigham and Women's Hospital, 75 Francis Street, ASB1-3-078, Boston, MA 02115, United States

Received 28 November 2006; received in revised form 2 February 2007; accepted 7 March 2007. published online 14 April 2007.

Abstract 

The purpose of this study was to provide a systematic review on prevention and treatment of uterine bleeding in the setting of hematologic malignancy.

We performed MEDLINE, PubMed, EMBASE and Cochrane searches with the terms uterine bleeding, uterine hemorrhage, hematologic malignancy. All identified literature sources were included in the review. The identified literature is largely comprised of case series and pilot studies. No evidence-based protocols for gynecologists and hematologists are available. The majority of the identified literature centers on menstrual suppression with GnRH agonists in hematologic malignancy, although no randomized trials could be identified. Review of the identified literature suggests that medical prevention with GnRH agonist therapy is highly effective for prevention of uterine bleeding in hematologic malignancy. With respect to treatment of acute uterine bleeding in the setting of hematologic malignancy, medical therapy can be used and is successful in the majority of patients, according to the identified studies. Surgical treatment should be used expeditiously if medical treatment options fail to control acute bleeding.

Empiric prevention and treatment algorithms for the discussed clinical settings are proposed. More research is necessary on the topic, with the goal to develop evidence-based guidelines for gynecology and hematology–oncology care providers. Close cooperation between the specialties may improve morbidity and mortality associated with uterine bleeding in hematological malignancy in the future.

Keywords: Uterine bleeding, Hematologic malignancy, Menstrual suppression, GnRH receptor agonists, Bone marrow transplant, Stem cell transplant

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-2115(07)00137-6

doi:10.1016/j.ejogrb.2007.03.012

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 134, Issue 1 , Pages 3-8, September 2007